This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Exact Sciences Croissance future
Future contrôle des critères 3/6
Exact Sciences devrait augmenter ses bénéfices et son chiffre d'affaires de 52.3% et de 9.1% par an respectivement. Le BPA devrait croître de de 52% par an. Le rendement des capitaux propres devrait être 15.1% dans 3 ans.
Informations clés
52.3%
Taux de croissance des bénéfices
52.03%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.3% |
| Taux de croissance des recettes | 9.1% |
| Rendement futur des capitaux propres | 15.13% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 24 Mar 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour de l'analyse • Mar 16
EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward
The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81. Analyst Commentary Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals.
Mise à jour de l'analyse • Mar 02
EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery
Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.Mise à jour de l'analyse • Feb 16
EXAS: Abbott Takeout Price And Downgrades Will Shape Event Path Forward
Analysts have maintained their $105 per share price target for Exact Sciences, with recent research emphasizing the agreed Abbott acquisition price of $105 as the key anchor for valuation and indicating limited expectations for additional upside. Analyst Commentary Recent research around Exact Sciences has shifted sharply toward viewing the agreed US$105 per share Abbott offer as the primary reference point for valuation, with many firms recalibrating their ratings and targets to that level.Mise à jour de l'analyse • Feb 02
EXAS: Takeout Premium And Downgrades Will Frame Upcoming Deal Closure Risk
Analysts made a modest upward adjustment to their fair value estimate for Exact Sciences to $105.81, describing it as largely in line with the $105 per share Abbott takeout price and supported by updated assumptions around discount rate, profit margin, and future P/E in recent research following the wave of rating downgrades tied to the announced acquisition. Analyst Commentary Street research around Exact Sciences has shifted quickly toward treating the shares as a deal proxy after the announced US$105 per share cash offer from Abbott.Mise à jour de l'analyse • Jan 19
EXAS: Abbott Takeover Agreement Will Anchor Upside To Deal Completion
Analysts have lifted their fair value estimate for Exact Sciences from $77.68 to $116.46. This reflects updated assumptions around slightly higher revenue growth, a revised profit margin outlook, a modestly higher discount rate, and a higher future P/E multiple in light of the agreed Abbott takeout price of $105 per share and the cluster of Street targets around that level.
Mise à jour de l'analyse • Jan 04
EXAS: Abbott Deal At $105 Will Define Shares With Balanced Prospects
Analysts have raised their price target on Exact Sciences to approximately $93 from about $48, citing the $105 per share Abbott takeout as validation of higher long term profitability and valuation multiples, despite slightly tempered standalone growth expectations. Analyst Commentary Bearish analysts largely framed the Abbott transaction as crystallizing value and limiting further upside, prompting a wave of rating downgrades to Hold, Neutral, Equal Weight, and Market Perform.Mise à jour de l'analyse • Dec 15
EXAS: Takeout Premium Will Shift Focus To Deal Completion Risk Balancing Upside
Analysts have raised their price targets on Exact Sciences toward the agreed Abbott takeout price of $105 per share. This reflects improved growth and margin expectations alongside the belief that the acquisition premium fairly captures the company’s long term value.Mise à jour de l'analyse • Dec 01
EXAS: Acquisition By Abbott Will Shift Focus Toward Deal Closure And Approval
The analyst price target for Exact Sciences has increased from $82.10 to $103.67 following the announcement of its acquisition by Abbott for $105 per share. Analysts cite the takeover premium and strong strategic rationale as key drivers behind the upward revision.Seeking Alpha • Nov 20
Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know
Summary Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue growth, record Q3 results, and promising new products like CancerGuard but remains unprofitable with fierce competition in cancer screening. Abbott Laboratories seeks to revitalize growth and expand its diagnostics portfolio, betting on Exact Sciences' MCED technology and established products like Cologuard despite high acquisition costs. Maintain Hold ratings on both Exact Sciences and Abbott Laboratories; Exact shareholders benefit from the deal, while Abbott's upside depends on successful integration and MCED market adoption. Read the full article on Seeking AlphaArticle d'analyse • Nov 20
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exact Sciences Corporation ( NASDAQ:EXAS ) shares have been powering on, with a gain of...Mise à jour de l'analyse • Nov 17
EXAS: Revenue Momentum And Expanded Guidance Will Drive Shares Higher
Analysts have raised their price target for Exact Sciences from approximately $70 to $82, citing stronger-than-expected revenue growth, margin expansion, and several upward revisions in expectations following earnings. Analyst Commentary Recent analyst updates reflect growing optimism about Exact Sciences' prospects, particularly in light of strong revenue growth, expanded guidance, and successful execution across its core business lines.Mise à jour de l'analyse • Nov 01
EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data
Analysts have raised their price target for Exact Sciences to $70 from $60, citing continued strength in its core Cologuard franchise as well as expanding opportunities in cancer screening and detection. Analyst Commentary Recent analyst activity for Exact Sciences reflects a dynamic mix of optimism and caution, as the company continues to execute on its core strengths while navigating evolving market expectations.Mise à jour de l'analyse • Oct 18
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have raised their price target for Exact Sciences to approximately $70 from $65, citing strong momentum from new revenue opportunities and increased confidence in long-term growth drivers. Analyst Commentary Recent analyst actions on Exact Sciences reflect notable shifts in sentiment, both positive and cautious, following the company’s latest performance and strategic moves.Mise à jour de l'analyse • Oct 03
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised their price target for Exact Sciences, increasing it from $64.01 to $65.38. They cite incremental near-term revenue growth drivers, ongoing margin expansion, and improved cash flow prospects as key reasons for the upward adjustment.Mise à jour de l'analyse • Sep 12
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised Exact Sciences’ price target to $64.01, citing renewed optimism from the Freenome deal and Shield V2 data as potential growth catalysts despite near-term skepticism around CRC blood-test data, resulting in only a slight upward revision to fair value. Analyst Commentary Bullish analysts cite the Freenome deal and Shield V2 data as catalysts for renewed Street focus on execution, with multiple near-term revenue growth drivers, continued EBITDA margin expansion, improving cash flow, and possible estimate upside.Article d'analyse • Sep 08
Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders are no doubt pleased to see that the share price has bounced...Mise à jour de l'analyse • Aug 08
Humana, Centene And Medicare Coverage Will Increase Screening Access
Despite a slight rise in Exact Sciences’ future P/E ratio and a modest decline in its net profit margin, the consensus analyst price target remains unchanged at $64.60. What's in the News Exact Sciences raised full-year 2025 revenue guidance to $3.13–$3.17 billion, up from previous estimates of $3.07–$3.12 billion, reflecting strong business momentum (Key Developments, 2025-08-06).
Nouvelle analyse • Apr 27
Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes
Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals.Seeking Alpha • Aug 18
Exact Sciences: Cost Optimization And Product Strength
Summary Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segment. It raised adjusted EBITDA guidance for 2024, demonstrating confidence in continued sales momentum and profitability. It is likely to suffer from volatility risks as it continues to strike a balance between growth and profitability. The stock is a buy with a potential 27% upside also given the way it is improving its competitive position and leveraging AI for accelerating data analysis. Read the full article on Seeking AlphaSeeking Alpha • Jun 11
Exact Sciences: Still No Reason To Own
Summary We are revisiting oncology testing company Exact Sciences Corporation today for the first time in nearly a year and a half. The shares have been cut by more than half since last summer, despite revenue growth in the low teens and strong support from the analyst firm community. Is it time to buy the dip? An updated analysis around Exact Sciences follows in the paragraphs below. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 4,491 | 341 | 694 | 933 | 7 |
| 12/31/2027 | 4,107 | 248 | 327 | 757 | 10 |
| 12/31/2026 | 3,661 | 35 | 99 | 534 | 12 |
| 12/31/2025 | 3,247 | -208 | 357 | 491 | N/A |
| 9/30/2025 | 3,082 | -987 | 247 | 387 | N/A |
| 6/30/2025 | 2,940 | -1,005 | 170 | 306 | N/A |
| 3/31/2025 | 2,828 | -1,020 | 194 | 324 | N/A |
| 12/31/2024 | 2,759 | -1,029 | 75 | 211 | N/A |
| 9/30/2024 | 2,692 | -214 | 98 | 233 | N/A |
| 6/30/2024 | 2,612 | -175 | -15 | 119 | N/A |
| 3/31/2024 | 2,535 | -240 | -20 | 112 | N/A |
| 12/31/2023 | 2,500 | -204 | 32 | 156 | N/A |
| 9/30/2023 | 2,406 | -282 | -24 | 139 | N/A |
| 6/30/2023 | 2,301 | -432 | -108 | 73 | N/A |
| 3/31/2023 | 2,200 | -517 | -298 | -88 | N/A |
| 12/31/2022 | 2,084 | -624 | -438 | -224 | N/A |
| 9/30/2022 | 2,005 | -716 | -443 | -300 | N/A |
| 6/30/2022 | 1,938 | -735 | -437 | -300 | N/A |
| 3/31/2022 | 1,852 | -745 | -330 | -199 | N/A |
| 12/31/2021 | 1,767 | -596 | -238 | -102 | N/A |
| 9/30/2021 | 1,760 | -793 | -117 | 34 | N/A |
| 6/30/2021 | 1,712 | -829 | 30 | 156 | N/A |
| 3/31/2021 | 1,546 | -720 | 19 | 109 | N/A |
| 12/31/2020 | 1,491 | -824 | 71 | 136 | N/A |
| 9/30/2020 | 1,321 | -327 | -89 | 0 | N/A |
| 6/30/2020 | 1,131 | -165 | -238 | -111 | N/A |
| 3/31/2020 | 1,062 | -136 | -262 | -87 | N/A |
| 12/31/2019 | 876 | -213 | -284 | -112 | N/A |
| 9/30/2019 | 724 | -216 | N/A | -88 | N/A |
| 6/30/2019 | 623 | -221 | N/A | -62 | N/A |
| 3/31/2019 | 526 | -219 | N/A | -105 | N/A |
| 12/31/2018 | 454 | -175 | N/A | -69 | N/A |
| 9/30/2018 | 399 | -143 | N/A | -69 | N/A |
| 6/30/2018 | 353 | -124 | N/A | -70 | N/A |
| 3/31/2018 | 308 | -119 | N/A | -77 | N/A |
| 12/31/2017 | 266 | -114 | N/A | -72 | N/A |
| 9/30/2017 | 214 | -130 | N/A | -98 | N/A |
| 6/30/2017 | 169 | -141 | N/A | -118 | N/A |
| 3/31/2017 | 133 | -155 | N/A | -121 | N/A |
| 12/31/2016 | 99 | -167 | N/A | -130 | N/A |
| 9/30/2016 | 79 | -170 | N/A | -133 | N/A |
| 6/30/2016 | 63 | -175 | N/A | -145 | N/A |
| 3/31/2016 | 50 | -169 | N/A | -141 | N/A |
| 12/31/2015 | 39 | -158 | N/A | -134 | N/A |
| 9/30/2015 | 27 | -150 | N/A | -135 | N/A |
| 6/30/2015 | 14 | -139 | N/A | -119 | N/A |
| 3/31/2015 | 6 | -120 | N/A | -104 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: EXAS devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3.4% ).
Bénéfices vs marché: EXAS devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: EXAS devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de EXAS ( 9.1% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de EXAS ( 9.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de EXAS devrait être faible dans 3 ans ( 15.1 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/03/24 05:07 |
| Cours de l'action en fin de journée | 2026/03/20 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Exact Sciences Corporation est couverte par 27 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |